基于骨髓归巢仿生纳米医学的心肌梗死跨器官早期干预。

IF 9.6 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Huaiyu Jiang, Haonan Zhang, Weichang Xie, Bei Qian, Shixing Huang, Junjie Zhang, Zhaoxi Qi, Qiang Long, Yiming Zhong, Lan Chang, Yecen Zhang, Zhao Qiang, Xiaofeng Ye
{"title":"基于骨髓归巢仿生纳米医学的心肌梗死跨器官早期干预。","authors":"Huaiyu Jiang, Haonan Zhang, Weichang Xie, Bei Qian, Shixing Huang, Junjie Zhang, Zhaoxi Qi, Qiang Long, Yiming Zhong, Lan Chang, Yecen Zhang, Zhao Qiang, Xiaofeng Ye","doi":"10.1002/adhm.202501619","DOIUrl":null,"url":null,"abstract":"<p><p>Myocardial infarction (MI) elicits a robust inflammatory cascade, necessitating immunomodulatory strategies to attenuate neutrophil infiltration. Traditional invasive therapies, such as direct intramyocardial injections of anti-inflammatory factors or catheter-based local delivery of stem cells, are constrained by narrow therapeutic windows and can cause local tissue irritation and myocardial injury due to mechanical manipulation or puncture. Moreover, intravenous administration of anti-inflammatory agents often lacks specificity and targeted efficacy. Leveraging myeloma cell membrane-coated biomimetic nanomedicine encapsulating neutrophil chemotaxis inhibitors (MMNP@SB225002), a targeted therapeutic paradigm is engineered for the trans-organ early intervention modulation of the inflammatory cascade post-MI. By harnessing the bone marrow-homing (BMH) propensity, the therapeutic agent is efficiently trafficked to the bone marrow during the early post-MI response, markedly suppressing neutrophil mobilization. This strategy efficiently directs therapeutic agents to the bone marrow early after MI, significantly reducing neutrophil mobilization. By avoiding direct intervention at the infarction site and employing indirect modulation through peripheral immune organs, this approach sustainably mitigates myocardial fibrosis. The findings demonstrate that MMNP@SB225002 confers robust cardioprotection by alleviating post-MI inflammation. This innovative approach delineates a promising remote therapeutic strategy with substantial translational potential, underpinned by its enhanced safety profile.</p>","PeriodicalId":113,"journal":{"name":"Advanced Healthcare Materials","volume":" ","pages":"e01619"},"PeriodicalIF":9.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trans-Organ Early Intervention for Myocardial Infarction Based on Bone Marrow-Homing Biomimetic Nanomedicine.\",\"authors\":\"Huaiyu Jiang, Haonan Zhang, Weichang Xie, Bei Qian, Shixing Huang, Junjie Zhang, Zhaoxi Qi, Qiang Long, Yiming Zhong, Lan Chang, Yecen Zhang, Zhao Qiang, Xiaofeng Ye\",\"doi\":\"10.1002/adhm.202501619\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Myocardial infarction (MI) elicits a robust inflammatory cascade, necessitating immunomodulatory strategies to attenuate neutrophil infiltration. Traditional invasive therapies, such as direct intramyocardial injections of anti-inflammatory factors or catheter-based local delivery of stem cells, are constrained by narrow therapeutic windows and can cause local tissue irritation and myocardial injury due to mechanical manipulation or puncture. Moreover, intravenous administration of anti-inflammatory agents often lacks specificity and targeted efficacy. Leveraging myeloma cell membrane-coated biomimetic nanomedicine encapsulating neutrophil chemotaxis inhibitors (MMNP@SB225002), a targeted therapeutic paradigm is engineered for the trans-organ early intervention modulation of the inflammatory cascade post-MI. By harnessing the bone marrow-homing (BMH) propensity, the therapeutic agent is efficiently trafficked to the bone marrow during the early post-MI response, markedly suppressing neutrophil mobilization. This strategy efficiently directs therapeutic agents to the bone marrow early after MI, significantly reducing neutrophil mobilization. By avoiding direct intervention at the infarction site and employing indirect modulation through peripheral immune organs, this approach sustainably mitigates myocardial fibrosis. The findings demonstrate that MMNP@SB225002 confers robust cardioprotection by alleviating post-MI inflammation. This innovative approach delineates a promising remote therapeutic strategy with substantial translational potential, underpinned by its enhanced safety profile.</p>\",\"PeriodicalId\":113,\"journal\":{\"name\":\"Advanced Healthcare Materials\",\"volume\":\" \",\"pages\":\"e01619\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Healthcare Materials\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1002/adhm.202501619\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Healthcare Materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/adhm.202501619","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

心肌梗死(MI)引起强烈的炎症级联反应,需要免疫调节策略来减轻中性粒细胞的浸润。传统的侵入性治疗,如直接在心内注射抗炎因子或基于导管的干细胞局部递送,受到狭窄治疗窗口的限制,并且由于机械操作或穿刺可能导致局部组织刺激和心肌损伤。此外,静脉注射抗炎药往往缺乏特异性和靶向性。利用骨髓瘤细胞膜包被的仿生纳米药物包被中性粒细胞趋化抑制剂(MMNP@SB225002),一种靶向治疗范例被设计用于心肌梗死后炎症级联的跨器官早期干预调节。通过利用骨髓归巢(BMH)倾向,治疗剂在心肌梗死后早期反应期间有效地转运到骨髓,显著抑制中性粒细胞动员。这一策略有效地将治疗药物引导至心肌梗死后早期骨髓,显著减少中性粒细胞动员。通过避免在梗死部位进行直接干预,并通过外周免疫器官进行间接调节,这种方法可以持续减轻心肌纤维化。研究结果表明MMNP@SB225002通过减轻心肌梗死后炎症提供强大的心脏保护。这种创新的方法描述了一种有前途的远程治疗策略,具有巨大的转化潜力,并以其增强的安全性为基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Trans-Organ Early Intervention for Myocardial Infarction Based on Bone Marrow-Homing Biomimetic Nanomedicine.

Myocardial infarction (MI) elicits a robust inflammatory cascade, necessitating immunomodulatory strategies to attenuate neutrophil infiltration. Traditional invasive therapies, such as direct intramyocardial injections of anti-inflammatory factors or catheter-based local delivery of stem cells, are constrained by narrow therapeutic windows and can cause local tissue irritation and myocardial injury due to mechanical manipulation or puncture. Moreover, intravenous administration of anti-inflammatory agents often lacks specificity and targeted efficacy. Leveraging myeloma cell membrane-coated biomimetic nanomedicine encapsulating neutrophil chemotaxis inhibitors (MMNP@SB225002), a targeted therapeutic paradigm is engineered for the trans-organ early intervention modulation of the inflammatory cascade post-MI. By harnessing the bone marrow-homing (BMH) propensity, the therapeutic agent is efficiently trafficked to the bone marrow during the early post-MI response, markedly suppressing neutrophil mobilization. This strategy efficiently directs therapeutic agents to the bone marrow early after MI, significantly reducing neutrophil mobilization. By avoiding direct intervention at the infarction site and employing indirect modulation through peripheral immune organs, this approach sustainably mitigates myocardial fibrosis. The findings demonstrate that MMNP@SB225002 confers robust cardioprotection by alleviating post-MI inflammation. This innovative approach delineates a promising remote therapeutic strategy with substantial translational potential, underpinned by its enhanced safety profile.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advanced Healthcare Materials
Advanced Healthcare Materials 工程技术-生物材料
CiteScore
14.40
自引率
3.00%
发文量
600
审稿时长
1.8 months
期刊介绍: Advanced Healthcare Materials, a distinguished member of the esteemed Advanced portfolio, has been dedicated to disseminating cutting-edge research on materials, devices, and technologies for enhancing human well-being for over ten years. As a comprehensive journal, it encompasses a wide range of disciplines such as biomaterials, biointerfaces, nanomedicine and nanotechnology, tissue engineering, and regenerative medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信